PL EN


Preferences help
enabled [disable] Abstract
Number of results
2005 | 53 | 4 | 308-320
Article title

Peptide-based approaches to treat asthma, arthritis, other autoimmune diseases and pathologies of the central nervous system

Title variants
Languages of publication
EN
Abstracts
EN
In this review we focus on peptide- and peptidomimetic-based approaches that target autoimmune diseases and some pathologies of the central nervous system. Special attention is given to asthma, allergic rhinitis, osteoarthritis, and Alzheimer's disease, but other related pathologies are also reviewed, although to a lesser degree. Among others, drugs like Diacerhein and its active form Rhein, Pralnacasan, Anakinra (Kineret), Omalizumab, an anti-beta chain antibody 'BION-1', are described below as well as attempts to target beta-amyloid peptide aggregation. Parts of the review are also dedicated to targeting of pathologic conditions in the brain and in other tissues with peptides as well as methods to deliver larger molecules through the 'blood-brain barrier' by exploring receptor-mediated transport, or elsewhere in the body by using peptides as carriers through cellular membranes. In addition to highlighting current developments in the field, we also propose, for future drug targets, the components of the inflammasome protein complex, which is believed to initiate the activation of caspase-1 dependent signaling events, as well as other pathways that signal inflammation. Thus we discuss the possibility of targeting inflammasome components for negative or positive modulation of an inflammatory response.
Publisher

Year
Volume
53
Issue
4
Pages
308-320
Physical description
Contributors
author
author
author
author
author
author
References
Document Type
REVIEW
Publication order reference
Kristin Hauff, Manitoba Institute of Cell Biology, Cancer Care Manitoba, Winnipeg, Canada
Identifiers
YADDA identifier
bwmeta1.element.element-from-psjc-bc857dc1-9f39-3aa3-9729-7111d4e5be42
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.